Structure-activity relationship of P-glycoprotein substrates and modifiers

被引:238
作者
Seelig, A [1 ]
Landwojtowicz, E [1 ]
机构
[1] Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland
关键词
P-glycoprotein; multidrug resistance; Michaelis-Menten constant; K-m; maximal velocity; V-max; drug transport; P-gp ATPase activation; competitive binding; hydrogen bond formation;
D O I
10.1016/S0928-0987(00)00177-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The air-water partition coefficients, K-aw, highly correlated with the corresponding lipid-water partition coefficients, K-iw, and the critical micelle concentrations. CMC, were measured for 11 compounds for which the kinetic parameters of P-glycoprotein ATPase activation (Michaelis-Menten constant, K-m, and maximal velocity, V-max) had been determined previously in inside-out vesicles of CR1R12 Chinese hamster ovary cells. In addition, the hydrogen bond donor patterns (type I and type II) relevant for substrate recognition by P-glycoprotein were determined from the energy-minimized three-dimensional structure of these compounds. A linear relation between the air-water partition coefficient, K-aw, and the inverse of the Michaelis-Menten constant, K-m, was observed such that K-m-K(aw)similar to1. The maximal velocity, V-max, was shown to decrease with the number and strength of electron donor (hydrogen bond acceptor) groups in recognition patterns. If two substrates are applied simultaneously to P-glycoprotein the compound with the higher potential to form hydrogen bonds generally acts as an inhibitor. We conclude that partitioning into the lipid membrane is the rate-limiting step for the interaction of a substrate with P-glycoprotein and that dissociation of the P-glycoprotein-substrate complex is determined by the number and strength of the hydrogen bonds formed between the substrate and the transporter. (C) 2000 Elsevier Science BN. All rights reserved.
引用
收藏
页码:31 / 40
页数:10
相关论文
共 46 条
[1]  
AKIYAMA SI, 1988, MOL PHARMACOL, V33, P144
[2]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[3]   Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery [J].
Benet, LZ ;
Izumi, T ;
Zhang, YC ;
Silverman, JA ;
Wacher, VJ .
JOURNAL OF CONTROLLED RELEASE, 1999, 62 (1-2) :25-31
[4]   PEPTIDE BINDING TO LIPID BILAYERS - NONCLASSICAL HYDROPHOBIC EFFECT AND MEMBRANE-INDUCED PK SHIFTS [J].
BESCHIASCHVILI, G ;
SEELIG, J .
BIOCHEMISTRY, 1992, 31 (41) :10044-10053
[5]   The multidrug resistance protein family [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1999, 1461 (02) :347-357
[6]   Comparison of staurosporine and four analogues: Their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells [J].
Budworth, J ;
Davies, R ;
Malkhandi, J ;
Gant, TW ;
Ferry, DR ;
Gescher, A .
BRITISH JOURNAL OF CANCER, 1996, 73 (09) :1063-1068
[7]  
BURKERT U, 1982, ACS MONOGRAPH, V177
[8]   Studies on propafenone-type modulators of multidrug-resistance IV: Synthesis and pharmacological activity of 5-hydroxy and 5-benzyloxy derivatives [J].
Chiba, P ;
Tell, B ;
Jager, W ;
Richter, E ;
Hitzler, M ;
Ecker, G .
ARCHIV DER PHARMAZIE, 1997, 330 (11) :343-347
[9]   PRIMARY SEQUENCES OF 2 P-GLYCOPROTEIN GENES OF ENTAMOEBA-HISTOLYTICA [J].
DESCOTEAUX, S ;
AYALA, P ;
OROZCO, E ;
SAMUELSON, J .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 1992, 54 (02) :201-212
[10]  
ECKER G, 1995, WIEN KLIN WOCHENSCHR, V107, P681